Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

July 31, 2025

Study Completion Date

March 31, 2026

Conditions
Myasthenia Gravis, Generalized
Interventions
DRUG

Descartes-08

Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA

Trial Locations (15)

14226

Dent Neurologic Institute, Amherst

15212

Allegheny Health Network, Pittsburgh

19104

University of Pennsylvania, Philadelphia

23219

Virginia Commonwealth University, Richmond

27599

University of North Carolina, Chapel Hill

30912

University of Augusta, Augusta

32751

Neurology Associates, P.A., Orlando

33487

SFM Clinical Research, LLC, Boca Raton

33612

University of South Florida, Tampa

66160

University of Kansas Medical Center Research Institute, Kansas City

80045

University of Colorado Anschutz Medical Campus, Aurora

92011

Profound Research, Carlsbad

92697

University of California Irvine, Irvine

97239

Oregon Health & Science University, Portland

T6G2C8

University of Alberta, Edmonton

Sponsors
All Listed Sponsors
lead

Cartesian Therapeutics

INDUSTRY